We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eni (E) & Dompe Farmaceutici Partner to Drive Health Research
Read MoreHide Full Article
Eni SpA (E - Free Report) , Italy's leading energy company, and Dompé farmaceutici, a leading pharmaceutical firm, collaborated earlier this week in a significant move toward advancing health research.
Eni’s CEO Claudio Descalzi and Dompé farmaceutici’s executive chairman Sergio Dompé sealed the partnership by signing a letter of intent, affirming their commitment to prioritize the health and well-being of communities where Eni operates.
The collaboration builds upon the successful participation of both companies in the European Exscalate4Cov project, a critical project aimed at tackling challenges arising from the COVID-19 pandemic. Together, they will leverage their collective expertise in molecular modeling and high-performance computing to drive innovative solutions in the field of healthcare.
As part of the agreement, Eni will provide Dompé researchers with access to its laboratories, support from the company's specialized personnel and the utilization of its HPC5 supercomputer. The primary objective is to expedite the discovery of new medications and vaccines capable of responding more swiftly and effectively to future healthcare crises. Additionally, the agreement extends to the examination of health security in relation to emerging energy supply chains, as well as the regular monitoring of high-incidence infections in regions where Eni is actively present.
According to Eni, the signing marks another progression for the company in safeguarding the health and well-being of its workforce, in accordance with the principles of precaution, prevention and well-being promotion outlined in the United Nations 2030 Agenda's Sustainable Development Goals.
Matador Resources is among the leading oil and gas explorers in the shale and unconventional resources in the United States. The company’s prime intention is to create more value for shareholders and generate lucrative returns from the capital invested in unconventional plays. MTDR has witnessed upward earnings estimate revisions for 2023 and 2024 over the past 30 days.
Pioneer Natural Resources is a leading upstream energy firm with primary operations in the Permian basin, which is among the lucrative oil shale plays in the United States with fewer risks. Its total holding of more than 1 million net acres in the Permian basin will support long-term oil production growth. PXD has witnessed upward earnings estimate revisions for 2023 and 2024 in the past seven days.
Diamondback Energy is an independent oil and gas exploration & production company with its primary focus on the Permian Basin, where it has around 491,000 net acres. With an attractive production profile, favorable industry trends and FANG’s low breakeven economics, the margin of safety on investment is very high. The company has witnessed upward earnings estimate revisions for 2023 and 2024 in the past 30 days.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eni (E) & Dompe Farmaceutici Partner to Drive Health Research
Eni SpA (E - Free Report) , Italy's leading energy company, and Dompé farmaceutici, a leading pharmaceutical firm, collaborated earlier this week in a significant move toward advancing health research.
Eni’s CEO Claudio Descalzi and Dompé farmaceutici’s executive chairman Sergio Dompé sealed the partnership by signing a letter of intent, affirming their commitment to prioritize the health and well-being of communities where Eni operates.
The collaboration builds upon the successful participation of both companies in the European Exscalate4Cov project, a critical project aimed at tackling challenges arising from the COVID-19 pandemic. Together, they will leverage their collective expertise in molecular modeling and high-performance computing to drive innovative solutions in the field of healthcare.
As part of the agreement, Eni will provide Dompé researchers with access to its laboratories, support from the company's specialized personnel and the utilization of its HPC5 supercomputer. The primary objective is to expedite the discovery of new medications and vaccines capable of responding more swiftly and effectively to future healthcare crises. Additionally, the agreement extends to the examination of health security in relation to emerging energy supply chains, as well as the regular monitoring of high-incidence infections in regions where Eni is actively present.
According to Eni, the signing marks another progression for the company in safeguarding the health and well-being of its workforce, in accordance with the principles of precaution, prevention and well-being promotion outlined in the United Nations 2030 Agenda's Sustainable Development Goals.
Zacks Rank & Key Picks
E currently has a Zack Rank #5 (Strong Sell).
Some better-ranked stocks in the energy sector are Matador Resources Company (MTDR - Free Report) , Pioneer Natural Resources Company and Diamondback Energy Inc. (FANG - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Matador Resources is among the leading oil and gas explorers in the shale and unconventional resources in the United States. The company’s prime intention is to create more value for shareholders and generate lucrative returns from the capital invested in unconventional plays. MTDR has witnessed upward earnings estimate revisions for 2023 and 2024 over the past 30 days.
Pioneer Natural Resources is a leading upstream energy firm with primary operations in the Permian basin, which is among the lucrative oil shale plays in the United States with fewer risks. Its total holding of more than 1 million net acres in the Permian basin will support long-term oil production growth. PXD has witnessed upward earnings estimate revisions for 2023 and 2024 in the past seven days.
Diamondback Energy is an independent oil and gas exploration & production company with its primary focus on the Permian Basin, where it has around 491,000 net acres. With an attractive production profile, favorable industry trends and FANG’s low breakeven economics, the margin of safety on investment is very high. The company has witnessed upward earnings estimate revisions for 2023 and 2024 in the past 30 days.